Alkylating Agent-Induced Toxicity and Melatonin-Based Therapies

Front Pharmacol. 2022 Mar 23:13:873197. doi: 10.3389/fphar.2022.873197. eCollection 2022.

Javier Egea¹, Francisco López-Muñoz^{2

3}, Oscar Fernández-Capetillo^{4

5}, Russel J Reiter⁶, Alejandro Romero⁷

¹ Molecular Neuroinflammation and Neuronal Plasticity Research Laboratory, Research Unit, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria-Hospital Universitario de La Princesa, Madrid, Spain.
² Faculty of Health, University Camilo José Cela, Madrid, Spain.
³ Neuropsychopharmacology Unit, Hospital Doce de Octubre Research Institute (i+12), Madrid, Spain.
⁴ Genomic Instability Group, Spanish National Cancer Research Centre, Madrid, Spain.
⁵ Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
⁶ UTexas Health San Antonio, Long School of Medicine, San Antonio, TX, United States.
⁷ Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain.

No abstract available

Keywords: alkylating agents; cancer; drug safety; inflammation; melatonin; molecular therapeutics; oxidative stress; toxicity.